Grief is a universal human experience, and yet is often a topic clinicians and the general public are not well versed in. Grief brings painful yet entirely natural emotions and physical experiences, which people can heal and grow through. So, the role of the mental or primary care health professional is usually supportive, helping patients to process the loss and to heal. In other words, grief is not generally a pathological experience unless particular vulnerabilities are exacerbated.

As is the case for all complex health outcomes, there are many risk factors known to increase risk of suicide. In Chapter 6, we will address the clinical assessment of suicide risk, which incorporates risk and protective factors. In the current chapter, we will show how risk factors – health and environmental – weave together and escalate risk at particular moments in a person’s life. This chapter will explore how the interaction of biological, psychological, and social/environmental risk factors can increase risk of suicide, differentiating between more enduring and more dynamic factors. We will show how these various factors intersect with life stressors to increase suicide risk. Research related to the global burden of suicide indicates that while cultural factors and available lethal means play a huge role in the suicide risk of a population, many risk and protective factors are shared cross nationally, likely simply being human risk factors for suicide.

For many complex health issues throughout history, misinformed views tend to promulgate, leading to a multitude of negative effects, deeply stigmatizing the experiences where these health issues are involved. Without science, untruths and stigma continue to thrive. In the past, before a body of scientific research led to an understanding of what drives suicide risk, many myths prevailed about suicide. These myths not only shaped stigmatized and erroneous views of suicidal behavior but resulted in harshly punitive ideas and judgment of people who experience suicidal thoughts, who attempt, or who ultimately lose their lives to suicide. Now that a multi-disciplinary group of scientific fields are shedding tremendous light on the actual drivers of suicide risk, cultural views are changing, bringing an understanding that while complex, suicide is a health issue.

Healthcare professionals manage medicolegal risk related to many different clinical issues and outcomes. Critical to risk management is an awareness of the duties we have as providers to our patients, and the steps that are considered standard practice for any particular clinical issue by similar health professionals. Included below are several considerations related to risk management and suicide related outcomes

All patient subpopulations are inherently “special” based on their unique constellations of clinical and demographic features that moderate and mediate treatment outcomes. This chapter will focus on diversity across distinct clinical subpopulations for which moderating or mediating factors do not simply provide information about the likelihood of a favorable drug response, but more specifically identify the need to adjust medication dosages or regimens, or favor certain medications over others based on evidence for safe and effective use in a particular patient group. Chronological age and biological sex assignment rarely in themselves signal the need for dosage adjustments, although associated features (e.g., diminished hepatic or renal function; pregnancy, premenstrual mood disturbances) may bear on a select evidence base for a given subpopulation. Metabolic (e.g., CYP450) enzymes also can vary by race, gender, age, and genetic polymorphisms, as noted in Chapter 8.

If the placebo effect is not the bane of every psychopharmacologist’s existence, it probably should be. Placebo responses largely negate all rules of pharmacodynamics, undermine theories about drug mechanisms of action, ruin clinical trials by causing failed (rather than negative) findings that mask the true potential for otherwise promising compounds, inflate costs for drug research and development, and generally give a black eye to neuroscience-based explanations for psychopathology. They also lend humility to clinicians’ assumptions that psychopharmacology reliably holds the upper hand when dealing with any and all matters of mental illness. In this chapter we will review known clinical features and correlates (if not actual predictors) of placebo responsivity across major psychiatric conditions, and offer guidance about how clinicians can anticipate, recognize and manage placebo effects – rather than ignore, dismiss, or otherwise struggle against them.

We have, we hope, covered a large but not unwieldy swath of territory of practical relevance for the everyday clinician trying to make pharmacological decisions informed by evidence. As illustrated throughout the preceding pages, the availability of empirical data to guide treatment decisions varies greatly within and across disorders. It probably matters more that clinicians know how to think empirically – that is, knowing when, where, and how to look up information pertinent to a given case – rather than try to tackle the impossible task of comprehensively knowing the ever-changing clinical trials database for all disorders. Wisdom equally involves recognizing when evidence is lacking, prompting reliance on opinion, extrapolation, and plausible rationales – but not conflating those guideposts with an empirical database.

It is time now to cull the principles we have tried to illustrate and summarize what we would consider to be basic maxims for practical psychopharmacology.

Psychiatrists probably are not so unusual among health care professionals in their desire to measure things. But compared to practitioners in most other areas of medicine, they may be the newest entrants to the world of the quantitative versus qualitative. Measurement-based care (MBC) and laboratory testing have become increasing focal points of clinical practice. Perhaps this comes in response to decades (if not centuries) of an often impressionistic and sometimes sluggishly qualitative way of recording clinical observations; perhaps it is backlash against a psychoanalytic heritage that for too long eschewed quantitative measures and formal outcome tracking; it also reflects the promulgation of research tools (semi-structured interviews, questionnaires, rating scales) into nonresearch clinical settings; and no doubt, MBC has arisen in response to a health care system that has come to link service reimbursement with quantifiable parameters.

Addictions are, fundamentally, disorders of the reward pathway. Clinicians, patients or family members are sometimes dissatisfied with the pronouncement that an addiction is its own diagnosis, preferring instead to search for additional psychiatric conditions (such as mood or anxiety disorders) from which addiction behaviors might be secondary offshoots – perhaps in part because of the more extensive range of pharmacotherapy options available to treat mood and anxiety disorders than addictions. True dual diagnoses certainly exist, in which mood or thinking problems occur as free-standing entities, but unless they chronologically antecede an addiction it becomes difficult if not impossible to discriminate them from the symptoms caused by repeated intoxication and withdrawal states. Still, intrinsic disorders of the reward pathway can be complex and often inherently involve problems with mood, thinking, perception, impulse control, self-regulation, compulsivity, and a host of psychopathology dimensions described in earlier chapters.

Diagnostic systems such as the DSM have long struggled over whether to organize psychiatric disorders as black-and-white categories defined by operational criteria (where “casehood” is unambiguously either present or absent) versus dimensions of psychopathology (where certain clinical elements are present but insufficient in number or duration to meet minimum criteria that define a particular clinical condition). Clinicians, meanwhile, often tend to identify and treat prominent symptoms, with varying degrees of awareness and concern about their broader context for defining the presence or absence of a distinct syndrome. In this chapter we will examine when pharmacological treatment targets can or should be thought of as unambiguous disease categories as opposed to dimensions of psychopathology that may not always be so clear-cut.

Diagnoses are clusters of signs and symptoms that should form a coherent constellation based on their inter-relationships.